The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 9, 2022. Its latest SEC filing is a 15-12B from Jun 3, 2022.
10-Q for Q1 FY2022, filed May 9, 2022
The sections below describe the company as of the FY2021 annual report.
Makes components for continuous glucose monitors and insulin-pump systems, along with other micromedical devices for medical-device manufacturers.
10-K for FY2021, filed Mar 7, 2022
Medical-device makers buy custom units, generally invoiced at shipment and paid under normal terms; some medical orders earn revenue as production progresses. Hearing and audio products are billed at shipment, while direct-to-consumer hearing aids generate revenue after the trial period and service plans are billed with the aid or on renewal.
10-K for FY2021, filed Mar 7, 2022Medical market products are invoiced when shipped and paid within normal commercial terms. The Company records a contract asset for revenue…View ↗
All of the Company’s products manufactured for the medical market are designed to each customer’s specifications, do not have an…View ↗
Nearly all of the Company’s products manufactured for the hearing health market can be reworked without significant cost and sold to…View ↗
The products manufactured for the professional audio market can be reworked without significant cost and sold to another customer in the…View ↗
The hearing health DTEC business offers a 60-day trial period to the end consumer for hearing aids, during which customers can return the…View ↗
The transaction price for hearing aid accessories and service plans is the invoiced amount. Variable consideration in the form of refunds…View ↗
10-K for FY2021, filed Mar 7, 2022
FY2021 revenue by product or service ↗$125.2M
10-K for FY2021, filed Mar 7, 2022
$125.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Diabetes
Recurring
10-K for FY2021, filed Mar 7, 2022 |
56%
FY2018: 57%
|
Diabetes, FY2021
$69.7M Sources
|
Recurring |
|
Interventional Catheters
Sold outright
10-K for FY2021, filed Mar 7, 2022 |
12% |
Interventional Catheters, FY2021
$14.6M Sources
|
Sold outright |
|
Medical Biotelemetry Other
|
11%
FY2018: 9.2%
|
Medical Biotelemetry Other, FY2021
$14.1M Sources
|
|
|
Hearing Health Value Based DTEC
|
2.8%
FY2018: 6.0%
|
Hearing Health Value Based DTEC, FY2021
$3.5M Sources
|
|
|
Hearing Health Value Based ITEC
Sold outright
|
6.4%
FY2018: 10%
|
Hearing Health Value Based ITEC, FY2021
$8M Sources
|
Sold outright |
|
Hearing Health Legacy OEM
Sold outright
|
8.7%
FY2018: 11%
|
Hearing Health Legacy OEM, FY2021
$10.8M Sources
|
Sold outright |
|
Professional Audio Communications
Sold outright
|
3.6%
FY2018: 6.4%
|
Professional Audio Communications, FY2021
$4.4M Sources
|
Sold outright |
Medical-device makers work with Intricon as joint development and manufacturing partners. Hearing products go to domestic manufacturers and distributors through its sales force, while its direct-to-consumer hearing business sells to consumers; international representatives solicit orders from European hearing, medical-device and audio manufacturers.
10-K for FY2021, filed Mar 7, 2022Intricon Corporation (together with its subsidiaries referred herein as the “Company”, or “Intricon”, “we”, “us” or “our”) is an…View ↗
Currently, Intricon sells some of its hearing device products directly to domestic hearing instrument manufacturers, and distributors and…View ↗
Internationally, sales representatives employed by Intricon GmbH, a wholly-owned German subsidiary, solicit sales from European hearing…View ↗
10-K for FY2021, filed Mar 7, 2022
For the years ended December 31, 2021 and 2020, one customer accounted for 64% and 63% respectively, of the Company's consolidated net…View ↗
No. It lost $106K in FY2021.
10-K for FY2021, filed Mar 7, 2022
$487KView ↗
10-K for FY2021, filed Mar 7, 2022
−$106KView ↗
10-K for FY2021, filed Mar 7, 2022
−$2.1MView ↗
10-Q for Q1 FY2022, filed May 9, 2022
−$657KView ↗
10-Q for Q1 FY2022, filed May 9, 2022
Open tableView ↗
8-K, filed May 24, 2022
ARDEN HILLS, Minn., May 24, 2022 -- Intricon Corporation (NASDAQ: IIN), an international joint development manufacturer engaged in…View ↗
Grew. Revenue grew 44% in 4 years, from $87M in FY2017 to $125.2M in FY2021, about 10% a year.
Broader micromedical focus
The older report centers body-worn devices for hearing, medical biotelemetry and professional audio; the latest describes a joint-development manufacturer of micromedical components, assemblies and final devices for medical-device manufacturers across a wider range of medical markets.
10-K for FY2018, filed Mar 14, 2019 10-K for FY2021, filed Mar 7, 2022IntriCon Corporation (together with its subsidiaries referred herein as the “Company”, or “IntriCon”, “we”, “us” or “our”) is an…View ↗
Hearing sales model
The older report describes a direct-to-consumer mail-order hearing-aid business; the latest says Hearing Help Express shifted to product development and testing, while the company also sells hearing devices through manufacturers, distributors and partnerships.
10-K for FY2018, filed Mar 14, 2019 10-K for FY2021, filed Mar 7, 2022Our DTEC represents a channel that sells products and services directly to the end consumer, which today consists of our HHE business. In…View ↗
Currently, Intricon sells some of its hearing device products directly to domestic hearing instrument manufacturers, and distributors and…View ↗
Loading...
